Results 111 to 120 of about 126,758 (293)

Targeting the ATX‐LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways

open access: yesAdvanced Science, EarlyView.
ABSTRACT Background Therapeutic resistance limits durable survival in advanced/metastatic renal cell carcinoma (RCC) treated with first‐line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI). We sought to define key resistance drivers and actionable targets.
Jinchen Luo   +16 more
wiley   +1 more source

A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignancies

open access: yesClinical & Translational Immunology
Objectives To evaluate the manufacturability, efficacy and safety of allogeneic CD19 chimeric antigen receptor double‐negative T cells (CD19‐CAR‐DNTs) as an off‐the‐shelf therapeutic cell product.
Dan Wang   +12 more
doaj   +1 more source

Phenotyping of P105-Negative B Cell Subsets in Patients with Systemic Lupus Erythematosus

open access: yesClinical and Developmental Immunology, 2012
This study aimed to investigate phenotype of RP105(−) B cell subsets in patients with systemic lupus erythematosus (SLE). Flow cytometry was used for phenotyping RP105-negaive B cell subsets.
Syuichi Koarada   +6 more
doaj   +1 more source

Humanized immune system animal models and their recent applications

open access: yesAnimal Models and Experimental Medicine, EarlyView.
In this review, we provide an updated and comprehensive overview of the current state of humanized immune system animal model research. We discuss the variety of techniques used to produce humanized mice with their respective strengths and weaknesses, and evaluate the advantages and limitations of these models, including issues with incomplete immune ...
Nicolas Skuli   +6 more
wiley   +1 more source

From Marginal to Central: Marginal Zone‐like B Cells as Critical Targets in Cladribine‐Treated Multiple Sclerosis

open access: yesAnnals of Neurology, EarlyView.
Objective Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood.
Marta Pirronello   +20 more
wiley   +1 more source

CD19 [PDF]

open access: yesScience-Business eXchange, 2009
openaire   +2 more sources

Plant Virus Immunotherapy for HPV‐Associated Oropharyngeal Squamous Cell Carcinoma

open access: yesAdvanced NanoBiomed Research, EarlyView.
Cowpea mosaic virus (CPMV) nanoparticles are safe and potent cancer immunotherapy candidates with strong immunomodulatory activity. CPMV activates innate immunity, which in turn drives adaptive immune responses and promotes durable, systemic antitumor effects.
Jessica Fernanda Affonso de Oliveira   +7 more
wiley   +1 more source

Cold Gas Plasma Induces Platelet Activation and Hemostasis in Native and Anticoagulated Human Blood

open access: yesAdvanced NanoBiomed Research, EarlyView.
Cold physical gas plasma induces platelet activation and hemostatic responses in native and anticoagulated human blood. Treatment efficacy depends on plasma parameters, including gas composition, distance, and exposure mode, which govern reactive species delivery and energy transfer.
Sander Bekeschus   +5 more
wiley   +1 more source

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T

open access: yes, 2019
Immunotherapy with chimeric antigen receptor-engineered T-cells (CAR-T) is under investigation in multiple myeloma. There are reports of myeloma remission after CD19 CAR-T therapy, although CD19 is hardly detectable on myeloma cells by flow cytometry (FC)
Nerreter, Thomas   +7 more
core   +1 more source

Single‐Cell Level Characterization of B Cell Depletion and Repopulation Following Rituximab in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy